文献速递心力衰竭与心肌病

ESC HF III 注册研究:射血分数降低、轻度降低和保留的心力衰竭结局

Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.
PubMed 文献 · Eur Heart J · 2026-01-01

该研究基于 ESC HF III 注册研究,纳入 41 国 220 中心 10,162 例心衰患者,按射血分数分为 HFrEF(58%)、HFmrEF(17%)和 HFpEF(25%)。急性心衰住院死亡率 5.1%,射血分数越低死亡率越高;随访 1 年,急性心衰出院后事件率高于门诊心衰,再住院率 14–44%。

要点

  • 急性心衰住院死亡率 5.1%,HFrEF 5.2%、HFmrEF 4.8%、HFpEF 3.4%。
  • 急性心衰出院后 1 年全因死亡率 16–22/100 患者年,门诊心衰 3.9–6.6/100 患者年。
  • 至少一次心衰再住院率急性心衰 36–44%,门诊心衰 14–21%。

核心结论

  • 欧洲及 ESC 附属国家心衰患者住院死亡率为 5.1%,射血分数越低死亡率越高。
  • 急性心衰出院后和门诊心衰随访 1 年,全因死亡 3.9–22/100 患者年,心血管死亡 1.7–13/100 患者年,不明原因死亡 0.8–6.3/100 患者年。
  • 至少一次心衰再住院率 14–44%,急性心衰后为门诊心衰后的两倍。

研究设计与样本

  • ESC HF III 注册研究为前瞻性观察性注册研究。
  • 39% 为急性心衰,61% 为门诊心衰;HFrEF 58%、HFmrEF 17%、HFpEF 25%。

主要发现

  • 急性心衰住院中位 9 天(IQR 6–14),住院死亡率 5.1%(HFrEF 5.2%、HFmrEF 4.8%、HFpEF 3.4%)。
  • 急性心衰出院后中位随访 376 天(IQR 360–432),全因死亡率 HFrEF 19、HFmrEF 22、HFpEF 16/100 患者年。
  • 门诊心衰全因死亡率 HFrEF 6.6、HFmrEF 4.0、HFpEF 3.9/100 患者年。
  • 至少一次心衰再住院率:急性心衰 HFrEF 44%、HFmrEF 42%、HFpEF 36%;门诊 HFrEF 21%、HFmrEF 14%、HFpEF 18%。

临床怎么用

  • 应重视急性心衰住院期间死亡风险,尤其射血分数降低患者。
  • 急性心衰出院后 1 年事件率高,需加强出院后随访和管理。
  • 门诊心衰患者也应持续监测再住院和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: To assess in-hospital and 1-year cause-specific outcomes in the contemporary European Society of Cardiology (ESC) Heart Failure (HF) III Registry. METHODS: Patients were enrolled in European or ESC affiliated countries and characterized in detail regarding clinical characteristics and cause-specific outcomes. RESULTS: Between 1 November 2018 and 31 December 2020, 10,162 patients were enrolled from 220 centres in 41 countries. Of these, 39% had acute HF ('AHF', age 70 [62-79] years, 36% women) and 61% had out-patient visit for HF ['out-patient HF', age 66 (58-75) years, 33% women]. Overall, 58% had HF with reduced ejection fraction (HFrEF), 17% HF with mildly reduced ejection fraction (HFmrEF), and 25% HF with preserved ejection fraction (HFpEF). In AHF, median [interquartile range (IQR)] duration of hospitalization was 9 (6-14) days, and 5.1% died in hospital (HFrEF 5.2%; HFmrEF 4.8%, HFpEF 3.4%). In AHF discharged alive and in out-patient HF, after a median (IQR) follow-up of 376 (360-432) days, all-cause, cardiovascular (CV), and unknown-cause mortality rates per 100 patient-years were as follows: AHF HFrEF: 19, 13, and 3.0 per 100 patient-years. The corresponding numbers were in AHF HFmrEF: 22, 11, and 6.3; AHF HFpEF: 16, 7.0, and 4.7; out-patient HFrEF: 6.6, 4.3, and 0.9; out-patient HFmrEF: 4.0, 2.6, and 0.8; out-patient HFpEF: 3.9, 1.7, and 1.2. At least one (re-)hospitalization for HF was experienced in 44% AHF HFrEF, 42% AHF HFmrEF, 36% AHF HFpEF, 21% out-patient HFrEF, 14% out-patient HFmrEF, and 18% out-patient HFpEF. CONCLUSIONS: In HF in Europe and affiliated countries, in-hospital mortality was 5.1% and greater with lower ejection fraction. Among hospital survivors and out-patients over 1 year of follow-up, event rates per 100 patient-years varied for death, 3.9-22, CV death 1.7-13, and unknown cause of death 0.8-6.3. The percent of patients that were (re-)hospitalized for HF at least once over 1-year follow-up ranged 14-44% and was twice as high post-AHF compared with post-out-patient visit.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lund LH, Maggioni AP, Crespo-Leiro MG, et al. Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry. Eur Heart J. 2026. PMID: 41736503. doi:10.1093/eurheartj/ehaf1074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。